A multicenter phase II study of bortezomib in ecurrent or metastatic sarcomas

Cancer

Volumn 103, Issue 7, 2005, Pages 1431-1438

  Maki, Robert G ^a   Kraft, Andrew S ^b,e   Scheu, Kelly ^a   Yamada, Jennifer ^a   Wadler, Scott ^c   Antonescu, Cristina R ^a   Wright, John J ^d   Schwartz, Gary K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Bortezomib; Pharmacokinetics; Phase II; Proteasome; Sarcoma

Indexed keywords

ALKALINE PHOSPHATASE; BORTEZOMIB; DOXORUBICIN; IFOSFAMIDE; PROCHLORPERAZINE; PROTEASOME INHIBITOR;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER PAIN; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONSTIPATION; COUGHING; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DOSE CALCULATION; DYSPEPSIA; DYSPNEA; EDEMA; EWING SARCOMA; FATIGUE; FEMALE; FEVER; FLATULENCE; HEADACHE; HEARTBURN; HUMAN; INFECTION; INSOMNIA; MALE; MULTICENTER STUDY; MYALGIA; NEUROPATHY; OSTEOSARCOMA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; RECURRENT CANCER; RHABDOMYOSARCOMA; SARCOMA; SIDE EFFECT; SOFT TISSUE SARCOMA; STOMATITIS; THORAX PAIN; TREATMENT OUTCOME; URINARY FREQUENCY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BORONIC ACIDS; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NERVOUS SYSTEM DISEASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SARCOMA; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME;

EID: 15744364211     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20968     Document Type: Article

References (21)

1. Brennan MF, Alektiar KM, Maki RG. Soft tissue sarcoma. In: DeVita VT Jr., Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 6th edition. Philadelphia: Lippincott Williams & Wilkins, 2001:1841-1891.
2. Verweij J, Seynaeve C. The reason for confining the use of adjuvant chemotherapy in soft tissue sarcoma to the investigational setting. Semin Radiat Oncol. 1999;9:352-359.
3. Patel SR. Systemic therapy for advanced soft-tissue sarcomas. Curr Oncol Rep. 2002;4:299-304.
4. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood. 2004;103:20-32.
5. O'Connor OA. The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas. Curr Treat Options Oncol. 2004;5:269-281.
6. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004;4:349-360.
7. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 2002;8:2505-2511.
8. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004;22:2108-2121.
9. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
10. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
11. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin Chem. 2000;46:673-683.
12. van Oosterom AT, Mouridsen HT, Nielsen OS, et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer. 2002;38:2397-2406.
13. Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer. 2003;39:2006-2011.
14. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342-4349.
15. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer. 2002;100:623-626.
16. Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004;22:1480-1490.
17. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.
18. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20:4420-4427.
19. Davis NB, Taber DA, Ansari RH, et al. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol. 2004;22:115-119.
20. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101:2377-2380.
21. Kamat AM, Karashima T, Davis DW, et al. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther. 2004;3:279-290.